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“The Child Is
Father of the Man”
(William Wordsworth, 1802)*
Harvey S. Hecht, MD
New York, New York
The occurrence of atherosclerosis at an early age has long
been the subject of curiosity and wonder. Isn’t it remarkable
that 65 of 140 combat soldiers who died as a result of
injuries sustained in World War I had increased coronary
atherosclerotic plaques at a mean age of 27.7 years (1)? How
interesting is it that grossly visible lesions not causing
obstruction were present in 35% of 300 Korean War
fatalities at an average of 22.1 years of age, with 39% having
10% to 90% stenosis, 3% total occlusion, and only 23% free
of grossly visible coronary lesions (2)! This curiosity quickly
dissipates despite confirmation by subsequent landmark
studies (3,4) and evidence that favorable risk factor profiles
early in life are associated with better outcomes (5,6).
ttention is quickly turned to the detection and treatment
f atherosclerosis in adults, at which point our best efforts
roduce only a 30% reduction in events compared with
lacebo in the primary prevention population (7).
See page 1364
Although dissatisfied with this inadequate event reduc-
tion, the cardiology community has been reluctant to seek
earlier risk stratification and intervention for several reasons.
First, because an event has not yet occurred, the cardiologist
believes that there still exists an ample window of opportu-
nity to lower low-density lipoprotein cholesterol (LDL-C)
and blood pressure (BP) and institute beneficial lifestyle
changes. Second, there is great reluctance to implement
aggressive evaluation and treatment of children and adoles-
cents for whom the specter of potential lifelong statin
treatment and drastic lifestyle changes appears daunting.
Third, there is no consensus regarding the appropriate risk
stratification tool for this age group. Finally, there have been
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However, there have been several studies linking child-
hood risk factors to subclinical atherosclerosis. In the
Muscatine study (8) of 346 men and 379 women 33 to 42
years of age, multivariable analysis using measurements
performed at 8 to 11 years of age identified total cholesterol
as a significant risk factor for increased carotid intima-media
thickness (CIMT) in men (odds ratio: 1.47) and women
(odds ratio: 1.71). The Cardiovascular Risk in Young Finns
Study (9) evaluated 2,229 white adults 24 to 39 years of age
who were examined at 3 to 18 years of age and underwent
CIMT 21 years later. In age- and sex-adjusted multivariable
models, CIMT in adulthood was significantly associated
with childhood LDL-C levels (p  0.001), systolic BP
(SBP) (p  0.001), body mass index (p  0.007), and
smoking (p  0.02) as well as with a number of risk factors
(p  0.001 for both men and women) and remained
significant after adjustment for contemporaneous risk vari-
ables. The Bogalusa Heart Study (10) of 486 subjects who
underwent CIMT at 25 to 37 years of age after initial entry
at 4 to 17 years of age reported odds ratios for the highest
versus lower 3 quartiles of CIMT of 1.42 for childhood
LDL-C and 1.25 for childhood body mass index. In 3
population-based, prospective cohort studies (11) of 1,711
adolescents 12 to 18 years of age who were remeasured as
young adults at 29 to 39 years of age, adolescent dyslipide-
mia status was more strongly associated with high CIMT in
adulthood than a change in dyslipidemia status. Using a
different modality, the Muscatine study (12) evaluated 384
subjects who had coronary risk factors measured at a mean
age of 15 years and coronary artery calcium scanning
(CACS) at a mean age of 33 years; coronary artery calcium
(CAC) prevalence was 31% in men and 19% in women. The
odds ratios for CAC in men and women were, respectively,
6.4 and 13.6 for the highest decile of body mass index, 6.4
and 6.4 for the highest decile of SBP, and 4.3 and 4.7 for
the lowest decile of high-density lipoprotein cholesterol.
In this issue of the Journal, Hartiala et al. (13) add
significantly to the subclinical atherosclerosis literature. The
authors performed CACS in 589 patients, 40 to 46 years of
age, from the Cardiovascular Risk in Young Finns Study.
Risk factor levels were measured at 12 to 18 years of age and
27 years later at the time of the CACS. Calcified plaque was
noted in 19.2%; men had twice the prevalence of women
(27.9% vs. 12.2%), as would be expected in a younger
population. Levels of traditional risk factors, including age,
SBP, total cholesterol, and LDL-C in adolescence, were
higher in those with CAC than those without CAC. In
adulthood, SBP, total cholesterol, diastolic BP, and pack-
years of smoking were higher in patients with CAC. Most
importantly, adolescence LDL-C and SBP predicted CAC
in adulthood independently of their interim changes, with
multivariable odds ratios of 1.34 (p  0.02) and 1.38 (p 
0.01), for 1-SD increase in adolescence LDL-C and SBP,
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hey concluded that “adolescence risk factor levels play an
mportant role in the pathogenesis of CHD.”
The identification of adolescent lipid and BP abnormal-
ties as the most important predictors of the extent of
ubclinical atherosclerosis 20 years later, irrespective of their
hanges over the intervening time period, is somewhat
ounterintuitive and implies that a tipping point has been
riggered at a very early age after which atherosclerosis is
ore likely to develop. Support for this concept may be
rovided by tracking correlation coefficients in the range of
nly 0.4 for cholesterol and BP from 5 to 10 years of age to
0 years later (14); their persistence as adult risk factors is
ar from certain. Obesity tracks best, with 84% of those
ith a body mass index in the 95th to 99th percentile
ange and 100% above the 99th as children continuing as
bese adults (14).
It is also important to acknowledge that a fundamental
iological truth still eludes our best efforts at discovery.
lthough risk factors increase the likelihood of disease
evelopment and the absence thereof renders disease devel-
pment less likely on a population basis, the relationship
reaks down when applied to the individual patient in
hom “all bets are off.” The determinants of susceptibility
o risk factors are unknown and may yet be the greatest
ontribution of the as-yet underperforming field of sophis-
icated genetic mapping. Fortunately, in the meantime,
ubclinical atherosclerosis imaging tells us who is susceptible
nd therefore requires treatment, even if it cannot provide
he reason for the susceptibility.
The issues raised by the Hartiala et al. study (13) are at
east as intriguing as the findings.
Surrogate Endpoints
The use of CAC rather than events is reasonable because
there are unequivocal data supporting CAC as the most
powerful risk stratifier (15), much more so than CIMT.
Moreover, the study is neither sufficiently powered nor of
long enough duration to allow for clinical outcomes. None-
theless, critics of subclinical atherosclerosis imaging are
likely to object to the use of a surrogate rather than a clinical
endpoint.
Are Risk Factors Enough?
A convincing theoretical argument against risk factor–based
risk stratification in adults is their relatively equal distribu-
tion in those in whom clinical disease does and does not
develop. The theory is borne out in reality by the absolutely
consistent demonstration of the superiority of CAC-based
prognostication to risk factors; CAC is atherosclerosis itself,
not merely a risk factor for the disease (15). Because there is
no reason to suspect a different pattern in adolescents, are all
adolescents with abnormal LDL-C and BP to be treated
similarly or is further risk stratification needed to determine
the nature and aggressiveness of the treatment? The adultcardiology community has not yet decided whether a sub-
clinical atherosclerosis–based algorithm or a treat-all phi-
losophy without further risk stratification is the most cost-
effective; this has not even been discussed in the child and
adolescent population.
Even if further risk stratification were desired, the choice
of modality is far from clear. Certainly, CAC and coronary
computed tomography angiography noncalcified plaque
evaluation has no role in this younger population. CIMT is
the most feasible but is still troubled by a lack of consensus
for study acquisition, inadequate training, considerably
poorer risk stratification potency than CAC, and relative
lack of data in the child and adolescent population. As
3-dimensional carotid ultrasound evolves, it may provide a
more potent tool, but it is still in its infancy. Endothelial
function has been evaluated in children (16), but clinical
utility has not been demonstrated for any population.
Treatment
Measurement of risk factors in children is valuable only if
beneficial therapeutic recommendations are implemented.
In 2011, the National Institutes of Health (NIH)–
sponsored Expert Panel on Integrated Guidelines for Car-
diovascular Health and Risk Reduction in Children and
Adolescents (14) recommended that all children should
undergo cholesterol screening once between 9 and 11 years
of age and once between 17 to 21 years of age; for patients
for whom lifestyle changes fail and who require lipid-
lowering medications, pharmacological treatment should be
considered at 10 years of age. BP should be measured in all
children annually between 3 and 18 years of age with drug
therapy as dictated by BP levels. Although only a small
percentage of children will require medication, this number
is likely to increase with the current explosion of obesity.
It is reasonable to assume that NIH guidelines–directed
risk factor measurement is honored much more in the
breach than in the observance; the screening as well as the
therapeutic recommendations are difficult to implement in
an overburdened pediatric office setting. Moreover, fears
have been raised about an avalanche of statin prescriptions
in this young population, particularly in the absence of
safety data for their prolonged administration, and, more
importantly, absence of beneficial outcome data. Fortu-
nately, the guidelines represent a triumph of common sense
over an absolute requirement for large-scale randomized
clinical outcome trials, which would be nearly impossible in
the childhood and adolescent population.
The extent of benefit from early LDL-C lowering may be
greater than anticipated. Ference (17), analyzing data from
1 million patients, used 9 single nucleotide polymor-
phisms from 6 genes associated with lower LDL-C as a
proxy for a treatment that lowers LDL-C beginning at birth
to simulate a “natural” randomized, controlled trial. All were
associated with a consistent 54% reduction in the risk of a
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Primordial Versus Primary Prevention
If risk factors in childhood and adolescence are the most
powerful determinants of atherosclerosis, future research
must focus on preventing the development of risk factors
(primordial prevention) rather than on the treatment of the
risk factors (primary prevention). “Indeed, childhood must
be a focus for primordial prevention research. Unless the
spread of risk factors is stemmed at this early age, the world
faces an epidemic of cardiovascular disease” (18). The
extraordinary projections of the Ference study (17) are based
on normalizing LDL-C at birth (primordial prevention) as
opposed to treating already established risk factors in
childhood and adolescence.
Conclusions
Studies further cementing the link between early risk factors
and later disease, similar to the present study by Hartiala et
al. (13), are to be encouraged and taken seriously. Until
effective genetic manipulation at birth is a reality (if ever),
implementation of the NIH guidelines offers the best hope
for a pervasive change in the continued epidemic of coro-
nary artery disease, which will be further accelerated by the
frightening increase in childhood obesity. It is incumbent on
society to reallocate resources away from the treatment of
established coronary disease to its prevention at the earliest
possible juncture. In the words of the poet William Word-
sworth in 1802, “the child is father of the man.”
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